Podcasts about biopharma

Burnham's debut, bond market jitters and the future of AI in BioPharma Markets were relatively quiet yesterday, but developments in the UK drew investor attention. Prime Minister Andy Burnham's policy announcements sparked concerns over the fiscal outlook, sending gilt yields higher, while John Healey's appointment as Chancellor raised fresh questions about economic policy. Meanwhile, semiconductor stocks rebounded, and oil prices swung sharply. Damien Ng from our Next Generation Research team joins us to discuss why AI's impact on BioPharma is likely to unfold over the coming years, rather than quarters.(00:00) - Introduction: Helen Freer, Product & Investment Content (00:34) - Markets wrap-up: Roman Canziani, Head of Product & Investment Content (07:08) - Genomics: Damien Ng, Next Generation Research (13:21) - Closing remarks: Helen Freer, Product & Investment Content Would you like to support this show? Please leave us a review and star rating on Apple Podcasts, Spotify or wherever you get your podcasts.

In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Smbat Rafayelyan, founder and CEO of Bioneex, about how AI is reshaping biopharma business development, deal scouting and asset evaluation.Business development has traditionally relied heavily on relationships, conferences, databases, analyst reports and manual search. But as therapeutic pipelines, publications, patent filings and global biotech activity expand, that old model is becoming harder to sustain. Smbat explains why teams that only rely on their network risk missing valuable assets before they even know they were available.The conversation explores how AI can act as a deal scout, helping biopharma and VC teams identify, structure and evaluate opportunities faster. Smbat explains how Bioneex allows biotech companies to submit non-confidential asset information, while AI extracts, validates and compares that data against external sources, curated databases and market intelligence.They also discuss where AI is most useful in the BD process. The aim is not to replace human judgement, but to reduce the overwhelming search space. If AI can narrow thousands of potential assets down to a small, relevant shortlist, expert teams can spend their time on the work that matters: diligence, strategic fit, deal judgement and human relationships.Smbat also warns that AI is not magic. General-purpose language models are not enough for serious deal sourcing. Effective AI scouting requires structured data, validation, multiple specialised models, human review and infrastructure built specifically for biopharma business development.Topics CoveredWhy traditional deal scouting is too slowThe limits of relationship-led deal flowHow AI supports asset search and evaluationMatching biotech assets with pharma and VC prioritiesWhy structured and validated data mattersAI use cases beyond drug discoveryNarrowing thousands of assets into focused shortlistsFailure modes of general-purpose AI in BDHow BD teams may change over the next few yearsWhy human judgement still matters in due diligenceEularis helps pharma and biotech leaders turn AI activity into board-defensible strategy and measurable commercial outcomes.If your organisation has plenty of AI in motion but very little that moves the commercial needle in a way the board can see, start with our 10-Day AI Diagnostic Sprint. It's a focused diagnostic that surfaces what's actually broken and what's blocking results, before you invest in a larger strategy effort.The Sprint diagnoses the problem. The AI Strategic Blueprint that follows is where we build the board-defensible strategy and plan.Details at eularis.com.AI platforms and tools solve specific problems. Strategy makes sure you're solving the right ones, in the right order. If you want help mapping priorities as you evaluate what to roll out next, send me a LinkedIn DM starting with ‘PRIORITIES' and two lines: what's already in flight, and the decision you're trying to make next.About the PodcastAI For Pharma Growth is the podcast from pioneering Pharma Artificial Intelligence entrepreneur Dr Andree Bates, created to help pharma, biotech and healthcare organisations understand how AI-based technologies can save time, grow brands, and improve company results.This show blends deep sector experience with practical conversations that demystify AI for biopharma leaders, from start-up biotech right through to Big Pharma. Each episode features experts building AI-powered tools that are driving real-world results across discovery, R&D, clinical trials, medical affairs, market access, regulatory, insights, sales, marketing, and more.Dr. Andree Bates LinkedIn | Facebook | X

In this episode of The Brand Called You, we welcome Justin Byers, Founder & CEO of Axio BioPharma, for an insightful discussion on transforming the biopharma industry through data coordination and infrastructure innovation. The conversation focused on lessons from Justin's experience at leading pharmaceutical companies, the challenges of fragmented process data, and why connecting siloed systems—not the science itself—is the industry's greatest hurdle.The discussion explored how a unique combination of biotechnology and cybersecurity expertise shaped Axio BioPharma's federated, vendor-neutral architecture. One key concept was the importance of providing a coordination layer that enables AI models to reach their full potential by connecting and structuring high-quality data across multiple platforms.A key theme that emerged was the importance of neutrality and trust when handling sensitive pharmaceutical data, and why large manufacturers cannot easily serve as neutral coordination layers. The conversation also explored the technical challenges of standardizing data across disparate systems, the parallels between the future of biomanufacturing and financial networks, and the value of firsthand operational experience.Tune in to discover how Justin and Axio BioPharma are bridging operational realities with digital innovation to accelerate breakthroughs in pharmaceutical manufacturing and AI-driven process development.

The antidote to a boring sex life isn't trying harder, it's trying something new together — Take the quiz at arya.fyi and use code: TRUTH15 for 15% off their guided intimacy subscription at https://arya.fyi/start?rfsn=8333683.c9f861In Part 2 of my conversation with Sabrina Johnson, founder, president, and CEO of Daré Bioscience (NASDAQ: DARE), we get into everything we didn't have time for in Part 1 — starting with the practical questions every woman actually wants answered about Dare to Play.We talk about how to use the sildenafil cream (where to apply it, what it feels like, and yes — what it tastes like if oral sex is on the table).Then we go wide. Sabrina walks me through the full Daré pipeline: Dare to Reclaim, a once-a-month vaginal ring delivering both progesterone and estradiol together (coming next year as a compounded prescription); a non-hormonal tamoxifen vaginal insert in development for breast cancer survivors who can't take estrogen; and Dare to Restore FloraSync LF5, a clinically studied vaginal probiotic launching this quarter.We also get into one of the most important consumer conversations I've had on this show: the truth about compounding. Compounded doesn't mean better — and Sabrina breaks down exactly what to ask when your doctor prescribes something, including whether the actual formula (not just the ingredient) has been clinically studied and published.And she closes with something I wasn't expecting — an invitation for anyone to invest in Daré Bioscience for as little as $250. Because if only 1% of healthcare dollars go to women's health, maybe it's time women funded it themselves.In This Episode:0:00 – Welcome Back & Part 1 Recap1:00 – How to Use Dare to Play: Where, How & What It Tastes Like4:00 – How Long Do the Effects Last?6:00 – Why Sabrina Founded Daré Bioscience9:30 – Dare to Reclaim: Once-a-Month Vaginal Ring for Menopause13:30 – A Non-Hormonal Solution for Breast Cancer Survivors16:00 – The Truth About Compounded Medications20:30 – How to Spot Junk Science & Ask Better Questions22:30 – Dare to Restore: Clinically Studied Vaginal Probiotic25:00 – Invest in Women's Health: Daré's Public Offering26:40 – Wrap UpAbout The Guest:Sabrina Martucci Johnson is a seasoned life sciences executive and passionate advocate for women's health innovation. As Founder, President,and Chief Executive Officer of Daré Bioscience, Inc. (NASDAQ: DARE), she leads a purpose-driven biopharmaceutical company dedicated to developing and commercializing novel, differentiated products for women. Under her leadership, Daré advances a diverse pipeline spanning contraception, fertility,menopause, sexual health, and vaginal health, with the goal of accelerating access to important therapies. Her leadership has been honored by Ernst &Young Entrepreneur of the Year (Pacific Southwest Region), Fierce Pharma'sMost Influential People in Biopharma, and inclusion on the Medicine MakerPower List and Endpoints Women in Biopharma. Driven by the belief that women deserve better options, Ms. Johnson champions innovation to transform how women worldwide experience their health and well-being.Connect with Sabrina Johnson:Website: https://darebioscience.comInstagram: https://www.instagram.com/darebioscienceDARE to PLAY™ Sildenafil Cream: https://daretoplaybio.comInvest: https://darebioscience.com/fundingAbout The Host:Karen Bigman, a Sexual Health Alliance Certified Sex Educator, Life, and Menopause Coach, tackles the often-taboo subject of sexuality with a straightforward and candid approach. We explore the intricacies of sex during perimenopause, post-menopause, and andropause, offering insights and support for all those experiencing these transformative phases.This podcast is not intended to give medical advice. Karen Bigman is not a medical professional. For any medical questions or issues, please visit your licensed medical provider.Looking for some fresh perspective on sex in midlife? You can find me here:Email: karen@taboototruth.comWebsite: https://www.taboototruth.com/Instagram: https://www.instagram.com/taboototruthYouTube: https://www.youtube.com/@taboototruthpodcastSubstack: https://karenbigman.substack.comLINKS, EXCLUSIVE VIP DISCOUNTS, COURSES & FREEBIES

The antidote to a boring sex life isn't trying harder, it's trying something new together — Take the quiz at arya.fyi and use code: TRUTH15 for 15% off their guided intimacy subscription at https://arya.fyi/start?rfsn=8333683.c9f861In this episode of Taboo To Truth, I sit down with Sabrina Johnson — founder, president, and CEO of Daré Bioscience — to tackle a question that's been 27 years overdue: where is the female equivalent of Viagra?Sabrina breaks down the critical distinction between libido (desire, the mental appetite for sex) and physical arousal (the body's blood flow response), explaining why the two require completely different solutions — and why the pharmaceutical industry has largely ignored the latter in women. She shares the science and story behind Dare to Play, a topical sildenafil cream engineered with proprietary Dermaflex technology to deliver the active ingredient directly to genital tissue, enhancing physical arousal sensations within 10–15 minutes.We cover how Dare to Play compares to existing options like Addyi, Vyleesi, and testosterone — and why none of those address physical arousal the way this does. We also clear up a common misconception: this is not a lubricant. It works from the inside out, enhancing the body's natural lubrication response through increased blood flow.Sabrina walks us through exactly how to get a prescription today — via your own provider or a free telehealth consult— and explains the pricing: $99/tube, 10 doses, roughly $10 per use. Currently out of pocket (no insurance), but intentionally priced for access.This is Part 1 of a two-part conversation you won't want to miss.In This Episode:0:00 – Ad: Aria.FYI0:55 – Welcome to Taboo to Truth1:30 – Meet Sabrina Johnson, CEO of Daré Bioscience2:15 – Libido vs. Physical Arousal: What's Actually the Difference?5:15 – The Real Reason There's No Female Viagra (Until Now)8:15 – Introducing Dare to Play: Sildenafil Cream Engineered for Women10:15 – How to Get a Prescription Today (Free Telehealth Consult)13:15 – What Does It Cost? The $99 Tube, $10 Per Use Breakdown15:15 – Dare to Play vs. Addyi, Vyleesi & Testosterone17:15 – Is This a Lubricant? No — Here's the Key Difference18:50 – Part 2 Is Coming — Subscribe NowWant a deeper look? Watch the full episode on YouTube for a more visual experience of today's discussion. This episode is best enjoyed on video—don't miss out!About The Guest:Sabrina Martucci Johnson is a seasoned life sciences executive and passionate advocate for women's health innovation. As Founder, President,and Chief Executive Officer of Daré Bioscience, Inc. (NASDAQ: DARE), she leads a purpose-driven biopharmaceutical company dedicated to developing and commercializing novel, differentiated products for women. Under her leadership, Daré advances a diverse pipeline spanning contraception, fertility,menopause, sexual health, and vaginal health, with the goal of accelerating access to important therapies. Her leadership has been honored by Ernst &Young Entrepreneur of the Year (Pacific Southwest Region), Fierce Pharma'sMost Influential People in Biopharma, and inclusion on the Medicine MakerPower List and Endpoints Women in Biopharma. Driven by the belief that women deserve better options, Ms. Johnson champions innovation to transform how women worldwide experience their health and well-being.Connect with Sabrina Johnson:Website: https://darebioscience.comDARE to PLAY™ Sildenafil Cream: https://daretoplaybio.comInstagram: https://www.instagram.com/darebioscienceAbout The Host:Karen Bigman, a Sexual Health Alliance Certified Sex Educator, Life, and Menopause Coach, tackles the often-taboo subject of sexuality with a straightforward and candid approach. We explore the intricacies of sex during perimenopause, post-menopause, and andropause, offering insights and support for all those experiencing these transformative phases.This podcast is not intended to give medical advice. Karen Bigman is not a medical professional. For any medical questions or issues, please visit your licensed medical provider.Looking for some fresh perspective on sex in midlife? You can find me here:Email: karen@taboototruth.comWebsite: https://www.taboototruth.com/Instagram: https://www.instagram.com/taboototruthYouTube: https://www.youtube.com/@taboototruthpodcastSubstack: https://karenbigman.substack.comLINKS, EXCLUSIVE VIP DISCOUNTS, COURSES & FREEBIES

Biopharmaceutical manufacturers are facing mounting pressure to scale production faster while maintaining quality and operational reliability due to the ever-expanding pipeline of therapies. Meanwhile, onshoring initiatives, increasingly complex facilities, workforce challenges, and rising demand for biologics are exposing limitations in traditional manufacturing approaches. As a result, organizations are rethinking how digital technologies, automation, and quality systems work together across the manufacturing enterprise. In this episode of Off Script, we spoke with Jim Masso, president and CEO of Honeywell Process Automation, about the operational challenges shaping the next generation of biopharma manufacturing. The conversation explores where manufacturers continue to encounter bottlenecks when scaling production, why workforce constraints and human error remain significant contributors to quality issues, and how AI-enabled process control and integrated digital quality systems can help improve reliability and accelerate facility startup. Masso emphasized the growing importance of connecting environmental controls, automation, and quality management, and stressed the organizational changes needed to fully realize the benefits of digital manufacturing. 

Send us Fan MailFor decades, oncologists have had to wait until cancer became visible on a scan before knowing whether it had returned. But what if doctors could detect microscopic traces of cancer months earlier with a simple blood draw - and use that information to decide who actually needs treatment? Today we're exploring a breakthrough that may fundamentally change the way cancer is monitored and treated.Eric Matthews is General Manager of Biopharma at Natera ( https://www.natera.com/ ), a leader in personalized molecular diagnostics and the company behind Signatera, the first FDA-approved molecular residual disease companion diagnostic.Over the past 25 years, Eric has helped bring nine medicines to market across nineteen indication launches, building a career at the forefront of oncology, precision medicine, and biopharmaceutical innovation.Before joining Natera, Eric served as Chief Business Officer at Caris Life Sciences, where he focused on diagnostic, data, and drug discovery partnerships. Prior to that, he was Chief Commercial Officer at Arcus Biosciences, helping forge major strategic collaborations including Arcus' landmark partnership with Gilead Sciences.Eric's previous leadership roles include Vice President of Global Marketing for Immuno-Oncology at AstraZeneca and commercial leadership positions at Genentech and Roche, where he worked on some of the most influential cancer therapies of the modern era, including Avastin and Tecentriq.Eric holds an MBA in Health Sector Management, a Master's in Health Policy and Economics, and dual bachelor's degrees in Molecular Biology and Economics from Duke University.Today we discuss the future of molecular residual disease testing, how personalized blood-based diagnostics are changing cancer care, the recent FDA approval of Signatera as the first MRD companion diagnostic, and what the next decade may hold for truly individualized oncology.#CancerResearch #CancerDetection #PrecisionMedicine #Oncology #LiquidBiopsy #Signatera #Natera #CancerCare #Biotech #HealthcareInnovation #Immunotherapy #Tecentriq #BladderCancer #MolecularBiology #PersonalizedMedicine #CancerTreatment #MedicalInnovation #FutureOfMedicine #Biotechnology #ProgressPotentialPossibilitiesSupport the show

Amid ongoing geopolitical uncertainty, regional manufacturing initiatives, and evolving supply chain risks reshaping the pharmaceutical industry, manufacturers are rethinking how biologics are produced and delivered around the world. Rather than relying on centralized production models, many organizations are expanding regional manufacturing footprints and developing more integrated production networks designed to improve resilience, reduce operational risk, and support long-term supply continuity.  In this episode of Off Script, we spoke with Jeff Mason, VP and head of the New Jersey Sales Office at Samsung Biologics, about how CDMOs are adapting to this changing landscape. The discussion follows Samsung Biologics establishing its first U.S. manufacturing presence through the acquisition of GSK's biologics facility in Rockville, Maryland, reflecting the broader industry shift toward regional manufacturing capacity. The conversation explores the growing importance of regional manufacturing strategies, why customers are increasingly seeking manufacturing redundancy from the outset of commercialization, how vertically integrated service models can simplify complex supply chains, and what the next generation of global manufacturing ecosystems could look like as companies balance efficiency with resilience.

We love to hear from our listeners. Send us a message.For episode 131 of Cell & Gene: The Podcast, we're sharing a recent "Better Biopharma" roundtable that Erin Harris had the opportunity to join alongside her Life Science Connect editorial colleagues. Hosted by Tyler Menichiello, this conversation brings together chief editors from across the Life Science Connect network to take a midyear look at what's shaping the pharmaceutical and biotech landscape in 2026. Featuring perspectives from Katie Anderson, Jeff Buguliskis, Ben Comer, Ray Dogum, Rachel Grabenhofer, Dan Schell, Anna Rose Welch, and Harris, this is a valuable listen for anyone looking to better understand where the industry is headed, and how CGT fits into that broader trajectory. https://www.bioprocessonline.com/solution/better-biopharmaSubscribe to the podcast!Apple  |  Spotify |  YouTubeVisit my website: Cell & GeneConnect with me on LinkedIn

Mike Schaefers, Chief Operating Officer at Simtra BioPharma, outlined what it takes to build durable CDMO partnerships in injectable manufacturing, why regional supply chains have become a permanent feature, and how early-phase collaboration directly shortens time to market.

Moderna's mRNA-based flu vaccine made headlines in February when the FDA declined to even review the application. Days later, the agency reversed course, setting a decision date for August and later scheduling an advisory committee meeting for June 18. In documents released ahead of that meeting, the FDA and Moderna seem to have reached alignment, though the agency did flag certain data gaps for advisors to review.Biotech IPOs are off the charts—literally. This past month has seen not one but two record-setting public debuts. First there was Kailera Therapeutics, which hit the market with $625 million in April, outpacing Moderna's 2018 IPO of $600 million. And now we have Parabilis Medicines, which last week dethroned Kailera as the largest biotech IPO of all time, with $670 million.Meanwhile, the number of employees laid off spiked by almost 50% year-over-year in May, though that jump is mostly due to significant cuts at Takeda and BioNTech.Genentech also made a big change last week.Eli Lilly continued its dealmaking spree with AlzeCure, striking a licensing agreement worth up to $1 billion centering on a small-molecule asset for Alzheimer's disease. But the bigger Lilly news in the past week was clinical results that show promise for the pharma's $2.3 billion acquisition of Ajax Therapeutics in April.Earlier this month, the FDA held a public session to glean feedback regarding the Commissioner's National Priority Voucher program, in which several groups called for a temporary pause to the pilot, citing concerns about transparency and political involvement. While the future of that program hangs in the balance, two voucher holders got updates this week. First, Sanofi's diabetes drug Tzield was greenlit for older kids and teenagers, though it's unclear whether a voucher was associated with the approval. Meanwhile, Disc Medicine's rejected rare disease drug bitopertin appears to be back on track, with the biotech announcing last week that the FDA will allow its current Phase 3 trial to support another regulatory filing.

As biopharma pipelines become more complex and market conditions continue to evolve, manufacturers are rethinking how they scale capacity, deploy capital, and build supply chains. The industry's focus is increasingly shifting toward developing the flexibility, resilience, and specialized capabilities needed to support rapidly evolving therapeutic modalities. At the same time, regionalization efforts, supply chain pressures, and changing sponsor expectations are prompting both CDMOs and drug developers to reassess long-term manufacturing strategies. In this episode of Off Script, we spoke with Sebastián Arana, executive vice president and global head of process solutions at MilliporeSigma, about the forces reshaping the biopharma CDMO landscape. The conversation explores the industry's shift from a capacity-driven market to a capability-driven one, how sponsors' expectations around speed and flexibility are changing manufacturing partnerships, and why process characterization, tech transfer, and supply chain coordination remain persistent scaling challenges. Arana also discusses the growing trend toward retrofitting existing facilities for multi-modality production, the rise of region-for-region manufacturing strategies, and more.

Warum der Darm darüber entscheidet, ob deine Nährstoffe ankommen Vor 20 Jahren hatten wir eine klare Philosophie: messen, was fehlt, auffüllen, fertig. Bei manchen funktionierte das. Bei anderen nicht, egal wie zuverlässig sie ihre Mischung nahmen. Ein Leistungssportler nahm seine individuelle Vitaminmischung jahrelang zuverlässig und seine Blutwerte verbesserten sich trotzdem nicht. Erst als wir den Darm aufgebaut hatten, kamen die Werte, die er nie hatte. Und das ganz ohne die Mischung. In dieser Folge erzähle ich, wie dieser Irrtum zur Gründung von Arktis BioPharma Schweiz geführt hat, die jetzt zehn Jahre alt wird. Vom ersten Aha-Moment mit den Stuhlanalysen über die SANUM-Therapie, die zu kompliziert war, bis zum Anruf eines hartnäckigen Aussendienstlers, der alles verändert hat. Kapitel der Episode 01:09 Der Ursprung von Arktis BioPharma Schweiz 07:58 Die Bedeutung des Darms für die Gesundheit 13:35 Die Gründung von Arktis BioPharma Schweiz und ihre Philosophie Was du daraus für dich mitnehmen kannst: Wenn der Darm nicht aufnimmt, hilft das beste Supplement nicht. Und Gesundheit geht in Stufen, nicht in Sprüngen. Faustformel: Erst das Fundament, dann die Bausteine. Nächste Woche ist Jubiläums-Aktionswoche. Jeden Tag 15 Prozent auf ein ausgesuchtes Produkt, die ganze Woche portofrei in der ganzen Schweiz. Welches Produkt an welchem Tag dran ist, erfährst du im Newsletter. Newsletter (mit 10 Prozent Gutschein zur Anmeldung): https://arktisbiopharma.ch/pages/newsletter  Folgenotizen: https://www.arktisbiopharma.ch/podcast Als Podcasthörer:in bekommst du von uns einen Rabatt auf unsere Produkte. Und zwar 15% Rabatt auf deinen ersten Einkauf (1-mal anwendbar, nur auf nicht bereits rabattierte Produkte). Der Gutscheincode ist in beiden Arktis BioPharma Shops in der SCHWEIZ und in DEUTSCHLAND gültig. Gib hierfür den Gutscheincode podcast15 ein, bevor du deine Bestellung abschliesst. Arktis BioPharma SCHWEIZ Arktis BioPharma DEUTSCHLAND Abonniere den Darmglück-Podcast in deiner Lieblings-Podcastapp (Apple Podcasts, Spotify, Deezer, Google Podcasts etc.), indem du "Darmglück" in die Suche eingibst.  

This episode of RBC Pathfinders in Biopharma explores how next-generation retinal gene therapies could transform treatment for patients with wet AMD and diabetic macular edema. CCBO of 4D Molecular Therapeutics, Chris Simms, discusses the promise of reducing the burden of frequent injections through long-lasting therapies designed to preserve vision for years. The conversation also examines the firm's commercial opportunity, global roll-out ambitions, and why sustained retinal care could reshape the future of retina.

On this episode of Inside Startup Investing, Chris Lustrino speaks with Dr. Michael Wyand, CEO of Oxeia Biopharma, a clinical-stage biotech company developing a potential breakthrough treatment for concussions and persistent concussion symptoms. Oxeia is leveraging ghrelin, a naturally occurring hormone involved in brain energy regulation and neural repair, to help heal the inflammation and cellular damage caused by traumatic brain injuries. With promising Phase 2a data showing an 85% responder rate among treated patients, the company is pursuing what could become the first FDA-approved pharmaceutical treatment specifically targeting concussion recovery. Chris and Michael discuss the science behind concussions, how brain damage occurs after impact, why “just rest” has remained the standard of care for decades, and how Oxeia's therapy could fundamentally change the treatment landscape for athletes, veterans, and millions of patients suffering from lingering neurological symptoms. They also dive into the company's clinical pathway, the business opportunity behind concussion therapeutics, the role of neurogenesis in recovery, and the broader future potential for treating conditions like CTE, Parkinson's disease, and ALS. If you want to understand the future of concussion recovery, brain health innovation, and biotech investing, this is an episode you won't want to miss.

Biopharma leaders are being asked to move faster, do more and compete in an AI-transformed world. The old agency model, building moats around capability and renting it back to clients, is cracking under that pressure. In this podcast, Woven Health Collective argues that the best agency partners in 2026 help build client capability, not dependency. They make the case for where real agency value lives now: deep scientific acumen, strategic judgment, flawless execution and the stewardship that keeps client capability current. A direct conversation for brand, medical and commercial leaders rethinking what they buy, what they build and what they demand from their partners. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

When a company proves it can see what others couldn't, the rules of drug development change overnight. Quantum BioPharma announced on May 18, 2026, that patient enrollment has reached the halfway mark in its collaborative imaging study with Massachusetts General Hospital, accompanied by encouraging preliminary results using a novel PET imaging technique capable of directly assessing demyelinated neurons with intact axons. The company's lead drug candidate, Lucid-MS, targets the underlying mechanism of multiple sclerosis—demyelination—rather than merely suppressing the immune system like most existing therapies. With an IND application submitted to the FDA on April 1, 2026, Quantum BioPharma is positioned at the intersection of breakthrough imaging science and first-in-class therapeutics.WHAT YOU NEED TO KNOWImaging Leap: PET scanning with [18F]3F4AP tracer provides up to 10x more accuracy than conventional MRI in measuring myelin damage and repair—potentially establishing a new FDA biomarker standard.Halfway Validated: First cohort successfully imaged at MGH showing robust signal in acute MS lesions; study completion expected within six months.First-in-Class: Lucid-MS targets PAD2 enzyme to prevent and reverse myelin breakdown—preclinical models demonstrated ability to help animals regain lost mobility.Commercial Scale: MS therapeutic market projected to exceed $38 billion by 2030, affecting 2.8 million patients worldwide with no current therapies addressing mobility restoration.STRATEGIC IMPLICATIONSThe MS treatment landscape is defined by what it cannot do. Virtually every approved therapy focuses on immune modulation—dampening the body's attack on its own myelin. But none address the underlying destruction happening to nerve fibers, and none restore lost mobility. Patients plateau on existing drugs, watching disease progression continue despite treatment. It's a multi-billion-dollar market built on managing symptoms, not reversing damage.Quantum BioPharma's approach disrupts that entire model. By targeting protein arginine deiminase 2 (PAD2)—the enzyme directly implicated in myelin degradation—Lucid-MS addresses neurodegeneration at its source. Phase 1 trials demonstrated a favorable safety profile. Preclinical models showed animals regaining the ability to walk. The oral formulation offers ease of administration versus injection-based competitors. And now, the MGH imaging partnership validates a tool that could measure myelin restoration in real time with unprecedented precision.CEO Zeeshan Saeed:“We've submitted the IND, we're at the halfway mark with MGH, and we're seeing preliminary imaging data that validates what we believed all along. This isn't about managing symptoms. It's about restoring what MS patients have lost. If this works—and we believe it will—we're talking about a fundamentally different standard of care.”INVESTOR TAKEAWAYQuantum BioPharma is executing on multiple fronts simultaneously: advancing a first-in-class therapeutic through FDA review, validating breakthrough imaging science with one of the world's premier hospitals, and preparing for Phase 2 initiation in a $38+ billion market with 2.8 million patients. The MGH study reaching its midpoint with encouraging preliminary results confirms the technical viability of precision myelin measurement. The IND submission positions Lucid-MS for near-term regulatory clarity. And the company's focus on demyelination—rather than immune suppression—addresses the core unmet need in MS: disease reversal, not just disease management. Quantum BioPharma offers investors exposure to a potentially transformative therapy at an inflection point in clinical and commercial validation.

Only one in three eligible lung cancer patients receives the targeted therapy they should get.That is not a failure of science.It is a failure of delivery.After more than two decades of precision oncology, biopharma has never had better tools: cell and gene therapy, in vivo CAR-T, antibody-drug conjugates, AI-enabled diagnostics, organoids, multi-omics, and global clinical data.Yet too many breakthroughs still fail to reach the bedside.Patients fall through fragmented systems.Data does not move cleanly.Community oncologists are overloaded.Tests are missed, delayed, or misread.Promising assets die in quarterly portfolio reviews.And healthcare systems built for pills, tablets, and chronic disease management are now being asked to deliver personalized medicine at scale.In this SPARK20 highlight episode, Alasdair Milton, PhD, Principal at KPMG and leader of the firm's Precision & Advanced Therapies practice, explains why the future of biopharma will not be decided by science alone.It will be decided by translation.From lab bench to boardroom.From data to decisions.From treatment to prevention.Alasdair brings more than 20 years of experience across life sciences strategy, commercial due diligence, precision medicine, advanced therapies, cell and gene therapy, biopharma M&A, diagnostics, and global healthcare transformation.This conversation moves from the precision medicine delivery crisis to China's biotech acceleration, from AI and organoids to trapped pharma assets, from lifelong wellness to the one skill every future biotech leader needs:The ability to translate complex science into business strategy, capital allocation, and patient impact.What You'll Learn in 22 MinutesWhy only one third of eligible lung cancer patients receive targeted therapy(00:01:53)And why precision medicine still breaks in everyday clinical practice.Why science keeps compounding even when systems fail(00:04:33)Including in vivo CAR-T, functional cures, gene therapy, and antibody-drug conjugates.Why innovation does not move in a straight line(00:05:20)How technologies can look dead for years before suddenly changing the market.Why China's biotech speed matters(00:07:36)How AI, organoids, scale, and execution are changing the global innovation map.Why great science dies inside Big Pharma(00:09:20)And how deprioritized assets can become billion-dollar companies when externalized properly.Why the industry must move from sickness to lifelong wellness(00:10:03)Alasdair's vision for a more proactive, preventive, data-driven healthcare system.Why pharma needs better ways to rescue shelved assets(00:13:06)Including examples such as SpringWorks, Cerevel, and new models for unlocking trapped value.How a 400-person Scottish island shaped Alasdair's worldview(00:15:07)The personal story behind his resilience, discipline, and leadership style.Why careers and companies are never linear(00:17:19)What Alasdair learned after moving to Boston and losing his role within weeks.Why the future belongs to translators(00:20:06)The most valuable skill in biotech: explaining complex science to business leaders, investors, and boards.How to connect with Alasdair Milton and the KPMG Precision & Advanced Therapies team(00:21:47)Quotes to Carry With You

Bakery Showcase is Canada's biggest baking show. Hosted by the Baking Association of Canada [https://www.baking.ca] (BAC), this well-known event is the ideal spot to catch up on the latest trends and innovations in the Canadian baking industry. In this episode of BAKED in Science, host Mark Floerke is joined by several bakery professionals to discuss bakery equipment, ingredients, and innovation solutions. Keith Ellis is the Director of Sales for Eastern Canada at Harvest Corporation (https://www.harvestbakeryequipment.com). Since 1964, Harvest Corporation has been committed to providing the food industry in North America and beyond with top-quality bakery equipment and exceptional service. Ender Ceber is the Founder and CEO of Chef Ceber, Inc. Chef Ceber (https://chefceber.com) is a premier chocolate and desserts brand created to bring traditional craftsmanship together with modern gastronomy. Spiromatic (https://www.spiromatic.com/en/) is a global leader in automated ingredient handling systems, specializing in flour storage, pneumatic conveying, dosing solutions, and sourdough systems for industrial bakeries and food manufacturers. E.B. Russell is the Senior Sales Manager at Lesaffre North America. The Lesaffre Group (https://lesaffrebaking.com) is a key global player in baking, food taste and pleasure, healthcare, and industrial biotechnology. Their family history spans over 170 years and in over 50 countries, and lives each day through our more than 11,000 employees. Mathias Weigel is the Head of International Sales at IREKS. IREKS (https://www.ireks.com/en/) is an internationally operating family company with its headquarters in Kulmbach, Germany, and customers in 90 countries worldwide. Stephen Brand is a Machine Operator at Barry Callebaut. Barry Callebaut (https://www.barry-callebaut.com/) is the world's leading maker of high-quality chocolate and cocoa products. Tina Tourangeau is the Client Development Manager, and Kate Tomic is the Business Team Director at Caldic North America. Caldic (https://www.caldic.com/en-us) powers innovation coast to coast by delivering tailored solutions and market-ready ingredients to the Life Sciences, Personal Care, and Biopharma markets. Arla Pro (https://www.arlapro.com/en/) is the dedicated food service business of the global dairy co-operative Arla Foods. Arla (https://www.arla.com) is a cooperative of dairy farmers who produce milk and dairy products for consumers worldwide. Daniel Moir is the Senior National Account Executive at Ardent Mills. Ardent Mills (https://www.ardentmills.com) is North America's leading flour supplier, producing multi-use flours, whole grains, and supported by 40+ flour mills and bakery-mix facilities. From the Show Floor While at the showcase, some topics covered include: Affordable bakery equipment Protein solutions for desserts Ingredient handling technology Fermentation Shelf-life extension Sourdough Bread mixes Chocolate products Ingredient supply Cheese ingredients for baking Cocoa replacement solutions

Guest: Barry Quart, CEO and DirectorCompany: Connect Biopharma, NASDAQ:CNTBWebsite: https://www.connectbiopharma.com/Connect Biopharma Bio:Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the Company is advancing rademikibart, a next-generation, potentially best-in-class antibody designed to target IL-4Rα. The Company is currently conducting global clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD, areas with significant unmet need. Connect has granted an exclusive license to Simcere Pharmaceutical Co., Ltd., for rademikibart in Greater China. Under the exclusive license and collaboration agreement, Connect is eligible to receive remaining milestone payments up to an aggregate amount of approximately $110 million upon the achievement of certain development, regulatory and commercial milestones. Connect is also eligible to receive royalties at tiered percentage rates up to low double-digit percentages on net sales in Greater China.Barry Quart Bio:Dr. Barry Quart brings over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. He has personally led several early-stage biotech companies through late-stage clinical development, regulatory strategy, highlighted by nine U.S. Food and Drug Administration (FDA) approved drugs.Dr. Quart was most recently CEO at Heron Therapeutics. He first served as CEO and Director starting 2012, transitioned to President and CEO in 2019 and was named Chair of the Board in October 2020. At Heron, Dr. Quart oversaw the development and approval of four drugs: two drugs for CINV (CINVANTI® and SUSTOL®) and two acute care drugs (ZYNRELEF® and APONVIE®). Prior to Heron, Dr. Quart co-founded Ardea Biosciences, Inc. in 2006 and served as its President and Chief Executive Officer and Director from its inception through its acquisition by AstraZeneca PLC in 2012. At Ardea, Dr. Quart invented and oversaw the development of a drug for gout (ZURAMPIC®), as well as the design and development of a series of MEK inhibitors for cancer that were licensed to Bayer AG. Dr. Quart currently serves on the Board of Directors of Kiniksa Pharmaceuticals. He is an inventor on 18 U.S. patents and an author on 75 publications and abstracts. Dr. Quart received his Pharm.D. from the University of California, San Francisco.

Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Download the transcript here

Dr. Stella Vnook, Co-Founder and Executive Chair of Kaida Biopharma, highlights the advantages for an early-stage biotech company to take a patient-centric perspective in drug development. She defines patient-centricity as focusing on whether a drug meaningfully improves a patient's life, which should influence decisions about trial design, endpoints, and side effects from the earliest stages. Kaida's work on a new treatment for ovarian cancer is designed to target tumor survival mechanisms and overcome treatment resistance, and has from the beginning taken into consideration the tolerability of treatments and the patient's quality of life. Stella explains, "We're so used to thinking drug-centric, and it's true that in the early stages of development, it's all about the molecule and the mechanism of action, and it's exciting to see how it works. But we really need to be thinking patient-centric because we will make decisions differently from the start. So it's not just about whether this drug works and how, but whether it meaningfully changes a patient's life. I think that's what patient-centric is or should be, because that would impact trial design, endpoints, and how we view tolerability or combination therapy."   "For ovarian cancer, women today may receive a variety of treatments. Now, let's talk about this for a second. It's the cancer that's usually diagnosed very late. That means the patient's tumor has already gone into the lymph nodes, and it's what we call a stage three PO4. The patients after surgery receive a variety of drugs such as platinum therapies or PARP, but they still may relapse, and they may become resistant to the therapy. Now, that initial therapy has probably had significant toxicity. Because they've become resistant to the therapy they received, now they have limited options. So fortunately, there are drugs that potentially could be eligible for FRA positive. There's been a lot of news about ELAHERE, which is great, but it's only 25% of the population, and many patients may never qualify for this treatment. So that's where Kaida comes in, because we're focusing on 80% of the population."  "Actually, the name Kaida is a dragon that eats its own tail. So that talks about the mechanism of action we've discussed: resistance. What we do is when the treatment has been given, it supports cell survival and actually eliminates the tumor's ability to replicate, which is called proliferation, causing it to destroy itself, which is called apoptosis. So in essence, the tumor disrupts itself because we're cutting off its support system." #Kaida #OvarianCancer #PatientCentric #OncologyInnovation #ProlactinReceptor #DrugDevelopment #AIinHealthcare #RealWorldEvidence #TolerabilityMatters #KaidaBiopharma #CancerCare Kaida-biopharma.com Listen to the podcast here

More than 175 new oncology targets surfaced at this year's American Association for Cancer Research annual meeting in San Diego, with the focus on new ways to enhance the immune response against solid tumors and to make existing immunotherapies more effective. On the latest BioCentury This Week podcast, BioCentury's analysts assess the new targets identified among the thousands of abstracts at AACR, as well as emerging pan-RAS inhibiting antibody-drug conjugates.The analysts also discuss Eli Lilly's latest deal — for a JAK-2 inhibitor from Ajax — and what the current pace of M&A and partnerships says about the state of biopharma dealmaking. This episode also features Kurma Partners' new venture fund and the latest in BioCentury's Emerging Company Profile series, spotlighting U.K.-based rheumatoid arthritis company Elevara Medicines. This episode of the BioCentury This Week podcast was brought to you by IQVIA Biotech.View full story: https://www.biocentury.com/article/659298#AACR #OncologyTargets #Immunotherapy #BiotechMA #ADC00:01 - Sponsor Message: IQVIA Biotech02:50 - AACR: New Targets11:08 - AACR: Pan-RAS Inhibitor ADCs15:35 - Biopharma Deals23:53 - Kurma's New Venture Fund27:28 - Emerging Company Profile: ElevaraTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Equity analyst Laura Nelson Carney uses her PhD in neuroscience to help spot medical innovation around the world. She brings a deep understanding of science to health care investing, using her research and drug development experience to help identify breakthrough drugs. And today, she's looking beyond biotechs in Boston and San Francisco and turning her attention to China as a growing source of innovation. #CapGroupGlobal This content is intended to highlight issues and be of a general nature. It should not be considered advice, an endorsement or a recommendation. Products mentioned are not an offer of the product and may not be available for sale or purchase in all countries. All investments have risk, and you may lose money. Past results are not a guarantee of future results. Statements attributed to an individual represent the opinions of that individual as of the date published and do not necessarily reflect the opinions of Capital Group or its affiliates. This content is published by Capital Client Group, Inc., and copyrighted to Capital Group and affiliates, 2026, all rights reserved. For more information, including our detailed disclosures, visit www.capitalgroup.com/global-disclosures For our latest insights, practice management ideas and more, subscribe to Capital Ideas at getcapitalideas.com. If you're based outside of the U.S., visit capitalgroup.com for Capital Group insights. Watch our latest podcast, Conversations with Mike Gitlin, on YouTube: https://bit.ly/4aKcZ2c U.K. investors can view a glossary of technical terms here: https://bit.ly/46s4Fmp To stay informed, follow us LinkedIn: https://bit.ly/4qQrPdH YouTube: https://bit.ly/3OJfg6m Follow Mike Gitlin: https://bit.ly/46onTta About Capital Group Capital Group was established in 1931 in Los Angeles, California, with the mission to improve people's lives through successful investing. With our clients at the core of everything we do, we offer carefully researched products and services to help them achieve their financial goals. Learn more: capitalgroup.com Join us: capitalgroup.com/about-us/careers.html Copyright © 2026 Capital Group

Synopsis: This episode is proudly sponsored by Quartzy. At a time when biotech innovation is being reshaped by science, capital, and global dynamics, Alok Tayi sits down with Barry Quart, CEO of Connect Biopharma, for a wide-ranging conversation on the future of asthma and COPD treatment. With over 30 years in pharmaceutical R&D and nine FDA-approved drugs to his name, Barry shares a rare insider perspective on building and scaling biotech companies—from pioneering HIV therapies that reshaped the AIDS epidemic to leading next-generation biologics targeting acute asthma exacerbations. He unpacks Connect's differentiated IL-4 receptor biology, the untapped opportunity in acute care settings, and why innovation has lagged for decades in treating exacerbations despite millions of ER visits annually. The conversation also explores the realities of running a publicly traded biotech in volatile markets, the evolving role of China in global drug discovery, and how leaders navigate geopolitical complexity while advancing science. As Connect approaches key clinical catalysts, this episode offers a compelling look at where biotech innovation, capital, and global strategy intersect. Biography: Dr. Barry Quart is the CEO of Connect Biopharma, (Nasdaq: CNTB), a clinical-stage company developing therapies for acute exacerbations of inflammatory diseases, such as asthma and COPD. Barry is currently leading the company's development of rademikibart, a best-in-class antibody that targets interleukin-4 receptor alpha (IL-4Rα) and reduces severe flare-ups called “exacerbations” that can occur with asthma and COPD and can lead to hospitalization and even death. Connect is the first company to enter this space addressing acute exacerbations of inflammatory diseases. Dr. Quart is a recognized industry leader with over 30 years of leadership experience and nine FDA-approved drugs under his belt. Barry brings deep expertise in drug development, biotech strategy, and bringing breakthrough therapies to the market. He holds a PharmD from the University of California, San Francisco.

During Episode 34 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2026 Q1 Report: Global Trends in Biopharma Transactions, covering capital markets, strategic deals, and regional trends.   Market Overview: Q1 2026 was defined by continuity rather than reversal. Licensing tied a three-year high, M&A recorded its strongest first quarter ever, and U.S. capital markets reopened meaningfully with the return of biotech IPOs. China's dominance in global licensing expanded further, while Europe and the UK remained challenged.  Strategic Transactions: Global licensing reached approximately $87B across 57 transactions, with greater than 90% of deal value concentrated in early-stage programs. China-based sellers drove 66% of global licensing value -up from 48% in full-year 2025 -with average deal values rising to ~$1.9B and upfront payments more than doubling sequentially to ~$179M.  M&A delivered the strongest Q1 on record at ~$50B, a 58% year-over-year increase. U.S.-based sellers accounted for 95% of deal value, with Phase 2 assets emerging as the leading contributor at 38% and oncology rebounding to 42% of deal value.  Capital Markets: Six U.S. biotech IPOs raised ~$1.8B -exceeding the full-year 2025 total. Venture financing surged 44% quarter-over-quarter to $5B, and reductions in force hit a three-year low of 34. In contrast, European venture financing fell 63% to $613M, with capital concentrated in a handful of late-stage financings.  Outlook: Strategic dealmaking remains strong, and capital markets are increasingly open, but deal structures will continue to favor milestone-heavy economics. China's structural role in global licensing and venture financing will shape partnership and exit strategies across the remaining quarters of 2026. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're exploring a fascinating realm where technology and biology converge, starting with a deepening relationship between biopharma and artificial intelligence. Novartis CEO Vas Narasimhan's recent appointment to the board of AI company Anthropic signals the strategic integration of AI into drug discovery and development processes. This collaboration highlights a growing trend where pharmaceutical companies are increasingly leveraging AI to optimize clinical trials, streamline drug discovery, and personalize patient care strategies. Similarly, Novo Nordisk has announced a strategic partnership with OpenAI to integrate AI technologies across various facets of its operations, including drug discovery and manufacturing. By leveraging OpenAI's machine learning capabilities, Novo Nordisk aims to streamline research efforts and accelerate therapeutic identification—a collaboration reflecting AI's growing role as an essential tool for maintaining competitiveness in drug development. Additionally, Amazon Web Services' launch of the Amazon Bio Discovery AI tool marks another milestone. Designed to expedite antibody design and drug discovery processes, it provides researchers with robust AI-driven platforms enhancing therapeutic design speed and accuracy. The emphasis on monoclonal antibodies aligns with industry trends focusing on targeted therapies for diseases such as cancer. Meanwhile, Eli Lilly's new obesity treatment, Foundayo, has caught the FDA's attention due to potential safety concerns. Despite progressing with its launch, the FDA has requested additional safety information to address unexpected serious risks associated with the drug. This highlights the ongoing regulatory scrutiny that accompanies novel treatments, especially in areas like obesity where patient populations are large and diverse. In another strategic move, Eli Lilly's acquisition of Crossbridge Bio for up to $300 million aims to bolster its oncology pipeline with dual-payload antibody-drug conjugates (ADCs). This acquisition reflects a strategic move enhancing Eli Lilly's position in oncology by integrating cutting-edge ADC technologies known for delivering cytotoxic agents directly to cancer cells while minimizing off-target effects. On another front, Travere Therapeutics is mapping a pathway to a potential $3 billion opportunity in the U.S. market following significant approval for its treatment Filspari, targeted at rare kidney diseases. This approval underscores the increasing focus on rare diseases, which present lucrative opportunities for pharmaceutical companies due to significant unmet needs and often high-cost treatments. Astellas' manufacturing strategy underscores the importance of reliable supply as a critical bridge from research to patient care. Led by Chief Manufacturing Officer Rao Mantri, this strategy highlights how manufacturing excellence can significantly impact drug availability and patient outcomes. It emphasizes that production reliability is vital in ensuring groundbreaking research translates into accessible medical treatments. In contrast, a slowdown in IPOs has been noted amidst an aggressive merger and acquisition spree by major pharmaceutical companies. This consolidation trend reflects strategic shifts within the industry as companies seek to bolster pipelines through acquisitions rather than organic growth. Such dynamics indicate a strategic pivot as firms prioritize acquiring promising assets over developing them from scratch. Ionis Pharmaceuticals' recent win in a drug naming competition exemplifies the complexities involved in branding within the pharmaceutical sector. Crafting a drug name that is memorable yet distinctive involves balancing marketability with regulatory requirements—a reflection of the intSupport the show

During the Asia-focused Episode 35 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2026 Q1 Report: Global Trends in Biopharma Transactions trends across China, Japan, and Korea.  China: Dominated global licensing with 66% of deal value -up from 48% in full-year 2025 -anchored by CSPC–AstraZeneca ($18.5B) and Innovent–Lilly ($8.5B). Venture financing surged to a three-year high of $1.2B across 17 deals, led by Corxel Pharmaceuticals' $287M oral GLP-1 Series D. Out-licensing remains the dominant business model, now structural and increasingly central to global biopharma dealmaking.  Japan: Biotech stocks outperformed pharma (+10% vs. +8%), and the IPO market reopened after 18 months with Innovacell and J-Pharma raising $112M combined. Japan-based buyers licensed three programs averaging $1.2B in deal value, with 100% from early-stage programs -reflecting growing appetite for pipeline diversification.  Korea: The KOSPI rose 17%, though biotech stocks fell 14%. Venture financing rebounded to $125M across six deals, up from just $18M in Q4 2025, concentrated in early-stage oncology. Korean sellers drove the majority of licensing activity from non-major markets with two early-stage transactions averaging $405M.  Regional Takeaway: Q1 2026 confirmed Asia-Pacific's rising centrality in global biopharma. China's record out-licensing drove global deal value, Japan reopened its public markets, and Korea showed early signs of a cautious recovery.  Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.  

John Newby is the CEO of Virginia Bio, the nonprofit statewide trade association that serves and promotes the life sciences industry in Virginia. VEDP President and CEO Jason El Koubi spoke with Newby about recent major life sciences announcements in Virginia, the Commonwealth's momentum in the biopharma manufacturing industry, and decisions and investments that led to Virginia's biopharma success.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the key changes shaping our industry, from a contraction in drug development pipelines to shifts in international trade policies, and what these might mean for the future of healthcare. Recent reports from Citeline indicate that for the first time in three decades, the R&D pipeline within biopharma is experiencing a contraction. This reduction marks a significant recalibration as companies seem to be strategically focusing on fewer but potentially more promising projects. This trend suggests a shift towards more streamlined and efficient development strategies, aiming to enhance success rates by channeling resources into high-value therapies. Such consolidation efforts reflect a broader industry movement towards optimizing pipeline portfolios to ensure that only the most viable candidates reach the market. In parallel, recent regulatory developments are capturing attention. The U.S. government has introduced a 100% tariff on imported drugs following a "Section 232" investigation. Although numerous exceptions have been included to mitigate potential disruptions, this move signals a protectionist stance aimed at encouraging domestic production capabilities. The policy could push U.S.-based companies to reevaluate supply chain dependencies and bolster local manufacturing, potentially reshaping global trade dynamics in pharmaceuticals. This strategy could also affect how companies prioritize their drug pipelines and navigate international collaborations essential for groundbreaking research. Meanwhile, across the pond in the U.K., a new agreement with the U.S. pharma sector has emerged as a significant development in international trade relations. By securing a tariff reprieve tied to increased drug spending through its National Health Service (NHS), the U.K. positions itself strategically to attract investments and stimulate economic growth post-Brexit. This aligns with global trends where healthcare policy adjustments are leveraged to secure favorable trade conditions. Turning to corporate strategies, BioNTech's closure of its Singapore vaccine facility highlights broader post-pandemic realignments. With declining global demand for COVID-19 vaccines due to widespread immunization, companies are optimizing resources and focusing on core competencies to better align with current market needs. This strategic pivot illustrates how companies are reassessing their global footprints and production capacities in response to evolving market dynamics. On the innovation front, Boehringer Ingelheim's continued focus on acquiring assets like Antibody-Drug Conjugates (ADCs) and T-cell Engagers (TCEs) underscores an investment in next-generation oncology treatments. These cutting-edge technologies offer enhanced precision in targeting cancer cells, potentially setting new standards in cancer care by improving patient outcomes. Strategic collaborations are also gaining traction in drug discovery, as evidenced by Eli Lilly's deepened alliance with Insilico Medicine—a deal valued at $2.75 billion. Such partnerships highlight the transformative potential of artificial intelligence (AI) in expediting drug development processes and enhancing predictive accuracy in early-stage research. AI-driven methodologies promise a new era of efficiency by streamlining R&D timelines and reducing costs. In another strategic move, Syneron Bio's recent Series B funding round underscores growing interest in peptide-based therapeutics. With $150 million secured to bolster its macrocyclic peptide platform, Syneron aims to enhance drug discovery processes by leveraging peptides' unique therapeutic window—offering specificity and reduced toxicity compared to small molecules or biologics. Amid these developments, mergers and acquiSupport the show

Program notes:0:38 Migrating biopharma industry1:36 Early stage development2:36 Need to replicate studies3:23 Treatment for fatigue from long Covid4:25 Fluvoxamine or metformin5:25 Only fluvoxamine helped6:25 Only for fatigue6:35 How treatments for hepatitis C have been used7:36 Number of people receiving treatment declining8:36 Need a better system9:16 Dulaglutide or tirzepatide and patient reported outcomes10:17 Quality of life metrics11:43 End

Biogen, Eli Lilly and Merck spent more than $20 billion in the past week to swallow biotechs with approved products or promising drug candidates—representing three of this year's four biggest takeovers. First, Merck picked up Terns Pharmaceuticals and its mid-stage leukemia drug for $6.7 billion. Then, on Tuesday, Lilly and Biogen struck, acquiring Centessa Pharmaceuticals and Apellis Pharmaceuticals respectively.Those big-ticket deals aren't the only recent transactions, however. Others include Novartis' up to $2 billion pick up of Excellergy and Gilead's $2.1 billion purchase of Ouro Medicines. Meanwhile, Kevin Tang—the newly minted CEO of Aurinia Pharmaceuticals—again has his sights set on Kezar Life Sciences, which he previously targeted in 2024. This time, biopharma's “clean-up” man is offering $50 million for the chronic disease–focused biotech.Last week also saw nods for Denali Therapeutics' Avlayah, the first treatment for Hunter syndrome to target the disease's neurological complications, and Rocket Pharmaceuticals' Kresladi for leukocyte adhesion deficiency-I. And it's been a big week for Biogen, which besides moving on Apellis, won approval of a high-dose formulation of spinal muscular atrophy drug Spinraza and scored a Phase 2 win for lupus candidate litifilimab in cutaneous lupus erythematosus.On the weight loss front, Wave Life Sciences' stock was cut in half after its obesity candidate WVE-007 failed to impress investors in a Phase 1 trial.

En Capital Intereconomía seguimos en directo la apertura del Ibex 35 y de las principales bolsas europeas, en una sesión marcada por el protagonismo empresarial y las tensiones en el sector tecnológico. En el análisis de mercados, David Cortina, responsable de Renta Variable de Santander Private Banking, destaca la fuerte subida de Grifols, que avanza un 9% ante los planes de sacar a bolsa su unidad Biopharma en Estados Unidos, una operación clave para aflorar valor. En paralelo, el sector tecnológico vuelve a estar en el foco por la escasez de chips, el aumento de precios y la crisis de helio, factores que presionan la cadena de suministro. En el ámbito corporativo, llama la atención el movimiento de Volkswagen, que explora su entrada en el sector defensa con conversaciones con un fabricante israelí vinculado al sistema Cúpula de Hierro, reflejando el giro estratégico de la industria en un contexto geopolítico complejo. El programa se completa con el consultorio de bolsa junto a Miguel Méndez, donde analizamos valores y resolvemos dudas de los oyentes.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant updates that underscore the dynamic nature of these industries, marked by scientific advancements, regulatory shifts, and strategic adjustments.A federal judge in Boston recently made headlines by halting key components of Robert F. Kennedy Jr.'s proposed vaccine overhaul. This decision has far-reaching implications for public health policy, particularly affecting the Health and Human Services' vaccination agenda and the Advisory Committee on Immunization Practices. The intervention highlights the complex interplay between legal frameworks and healthcare policies, especially in an era where vaccine strategies are pivotal for global health security. This judicial decision comes amid broader societal debates about vaccine safety, efficacy, and autonomy—issues that remain critical as we navigate ongoing public health challenges.In a major move within scientific innovation, Roche has partnered with NVIDIA to integrate artificial intelligence into drug and diagnostic development. By leveraging NVIDIA's AI capabilities, Roche aims to streamline its R&D processes, enhancing precision medicine approaches. This collaboration exemplifies the growing trend of incorporating advanced computational technologies in biopharma to optimize drug discovery and development pipelines. The potential reduction in time-to-market for new therapies could significantly impact patient care by accelerating access to innovative treatments.Turning to clinical trials, Pfizer's CDK4 inhibitor, atirmociclib, has shown promising results in a Phase 2 trial for second-line metastatic breast cancer. The trial met its primary endpoint of improving progression-free survival, signaling atirmociclib's potential as a therapeutic option. Pfizer's strategic focus on earlier lines of treatment indicates a shift towards expanding indications for promising drug candidates, which could enhance outcomes for a broader patient population. This development aligns with Pfizer's efforts to maintain its oncology portfolio amidst impending patent expirations on key products.Conversely, Rhythm Pharmaceuticals has faced setbacks with its MC4R agonist, Imcivree, which failed to meet primary BMI endpoints across four genetic obesity subgroups in a Phase 3 trial. This outcome underscores the challenges inherent in developing treatments for complex genetic conditions and highlights the necessity for robust clinical trial designs to accurately evaluate therapeutic efficacy.The geopolitical landscape also impacts the industry significantly. Ongoing tensions involving Iran pose risks to drug shipments from the Middle East, particularly those requiring cold chain logistics such as biologics and generics. This situation could have long-term repercussions on US manufacturing capabilities and generic drug availability. Companies must consider strategic adjustments in supply chain management and sourcing strategies to mitigate these risks.On the market strategy front, Biovie's plan for a $20 million IPO reflects an industry trend towards repurposing existing drugs to address unmet medical needs. By developing a new formulation of an approved low blood pressure drug for liver disease treatment, Biovie aims to optimize its mature product portfolio amid pricing pressures and competitive markets.Another significant regulatory development saw Alcon abandon its $356 million acquisition deal with Lensar following scrutiny from the Federal Trade Commission (FTC). This decision illustrates the regulatory challenges companies face in pursuing mergers and acquisitions. While regulatory oversight ensures market competitiveness, it necessitates careful strategic planning by companies seeking expansion through acquisitions.Further illustrating the evolving reSupport the show

Biopharma's weight loss warriors have led the news this week, with Structure Therapeutics and Rhythm Pharmaceuticals announcing new data. Structure delivered a “competitive profile” for its investigational GLP-1 pill compared to Eli Lilly's orforglipron and Novo Nordisk's oral Wegovy, BMO Capital Markets wrote to investors, after the candidate elicited 16.3% weight loss after 44 weeks in a Phase 2 trial. Rhythm was not as successful, announcing that Imcivree failed in a Phase 3 basket trial of various genetically driven obesities. Meanwhile, Lilly and Novo made headlines outside of the clinical realm, as Lilly warned the public of the potential safety risks of taking compounded versions of tirzepatide—marketed as Zepbound for obesity and Mounjaro for type 2 diabetes. And Novo was hit with an FDA warning letter for failing to investigate reported adverse events—including three deaths—potentially linked to its own diabetes drug Ozempic. The letter only adds to what has been a challenging recent run for Novo, one that led to a 34% drop in total assets under management for its controlling shareholder Novo Holdings. On the regulatory front, Robert F. Kennedy Jr.'s vaccine agenda is stalled after Massachusetts District Court Judge Brian Murphy found that his efforts to overhaul policies in this area were likely unlawful. Murphy specifically cited Kennedy's move last June to empty the CDC's Advisory Committee on Immunization Practices (ACIP). This comes on the heels of a White House crackdown in which officials would like the health secretary to tone down his vaccine skepticism, according to a report by The Wall Street Journal. At the FDA, tensions continue to escalate, with Sen. Ron Johnson (R-WI) launching an investigation into recent rejections of rare disease drugs. And transparency issues have come to light once again regarding the circumstances around biologics chief Vinay Prasad's imminent departure and recent request to remain anonymous during a media briefing about uniQure's gene therapy for Huntington's disease.

In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry and how the sector fared in 2025 overall. As the world’s 25 largest biopharma companies reported earnings, attention quickly shifted to their outlook for 2026. Only five drugmakers expect faster growth than in 2025, and some are projecting sales declines. One of the most surprising outlooks came from Novo Nordisk, which expects a significant drop in sales. Several other companies are also facing the loss of patent protection for blockbuster drugs, leading them to forecast either declining revenue or slower growth. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss the trends emerging from fourth-quarter earnings and how the industry’s performance compares with previous quarters. They also examine the intensifying GLP-1 competition between Novo Nordisk and Eli Lilly and how the two companies appear to be heading in opposite directions. To learn more about the topics in this episode: Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4 As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 Biopharma industry gathers momentum in Q3 In Q3, drugmakers saw a marked decline in US vaccine sales as Eli Lilly kicked into higher gear See omnystudio.com/listener for privacy information.

Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the global industry, even if this implies some level of rebalancing away from the U.S.? On the latest BioCentury This Week podcast, BioCentury's analysts discuss a Guest Commentary by McKinsey Senior Partner Emeritus Franck Le Deu, who argues that a multipolar biopharma world in which the U.S. continues to thrive even as China becomes meaningfully stronger can emerge.The analysts also discuss BioCentury's latest Rare Disease Spotlight, which focuses on a wave of therapies aiming to activate retinal function in Stargardt disease patients.Turning to FDA, BioCentury Washington Editor Steve Usdin discusses recent public statements by FDA Commissioner Marty Makary, questions about Vinay Prasad's future, and the plausible mechanism pathway.View full story: https://www.biocentury.com/article/658606 #GlobalBiopharma #ChinaBiotech #RareDisease #StargardtDisease #FDAPolicy 00:00 - Introduction02:47 - Multipolar Biopharma World13:39 - Rare Disease Spotlight25:15 - Makary Remarks31:14 - Plausible Mechanism FrameworkTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

AI and emerging technologies are reshaping biopharma and redefining how science is built, scaled and valued. As the landscape shifts, the industry must confront critical questions about leadership, capital strategy and what innovation really looks like in the years ahead. Join us to hear inside perspectives from senior leaders across biopharma and technology on: What's driving momentum at the intersection of tech and science Where unsolved challenges are creating the next wave of opportunity This event is designed for technology and life sciences leaders, investors and stakeholders who want to learn from peers, identify emerging opportunities, and understand how data and AI will shape the next phase of biopharma. Dress code (encouraged): Elevated business attire or cocktail wear. In celebration of Black History Month, MelanInScience and WeAre encourage attendees to wear skin tone-inspired shades to reflect the beauty and diversity of all complexions. Hosted by MelanInScience and WeAre. See more  Michelle Meow Show programs at Commonwealth Club World Affairs of California.   Learn more about your ad choices. Visit megaphone.fm/adchoices

This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

In this episode of the GSD Presents Silicon Valley AI & Tech series, we sit down with the visionary founders of Matrix Edge Therapeutics, Elaine Phan and Andreas Taylor.We dive deep into how they are building the "Signal → Cure → Longevity" AI infrastructure to revolutionize drug discovery and patient stratification. Learn how continuous patient signals and agentic AI are being used to reduce clinical trial-and-error, speed up cure development, and ultimately extend human healthspan.Key Topics Covered:The shift from reactive medicine to AI-driven Precision Medicine.How "Continuous Patient Signals" improve subtyping and stratification.The role of AI in streamlining the lifecycle from drug discovery to post-market management.The future of longevity and bio-tech innovation.About the Guests:Elaine Phan: Founder of Matrix Edge Therapeutics, Biopharma leader (20+ years), NIH AI strategist, and UC Berkeley/Stanford/Georgia Tech alumna.Andreas Taylor: Co-Founder & CTO, Genentech veteran, Data Scientist, and expert in agentic AI applications and drug delivery.Connect with GSD Venture Studios: gsdvs.com#PrecisionMedicine #AIinHealthcare #Longevity #DrugDiscovery #Biotech #GSDVS #TopGlobalStartups #HealthTech #BioPharma

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of breakthroughs and strategic maneuvers that are reshaping the landscape of this dynamic industry.Roche is making waves with its antibody Gazyva, initially recognized for cancer treatment. The company has successfully ventured into autoimmune diseases, targeting kidney conditions. Recent phase 3 trials have reinforced Gazyva's efficacy in treating immune-mediated kidney diseases, building on its prior approval for lupus nephritis. This marks a potential paradigm shift from oncology to autoimmune therapy applications, offering a promising new avenue for treating complex kidney disorders. Such advancements underscore the power of immune modulation in addressing severe health conditions.Turning to oncology, Eli Lilly is expanding the use of its cancer drug, Retevmo. Originally approved for specific lung and thyroid cancers with rare biomarkers, Lilly is now exploring its use in the adjuvant setting for non-small cell lung cancer. This effort reflects a broader trend in oncology: companies are increasingly looking to extend the application of targeted therapies beyond their initial indications. This expansion could significantly enhance treatment options and improve patient outcomes.In ophthalmology, Ocular Therapeutix is preparing for an FDA filing following positive phase 3 results for its wet age-related macular degeneration treatment. Their candidate, AXPAXLI, showed superior efficacy compared to Regeneron's Eylea in head-to-head trials. Despite investor skepticism, Ocular remains confident in its product's potential to impact retinal disease management positively. The competitive landscape in ophthalmology is fierce, and innovative treatments with substantial clinical benefits over existing therapies can redefine standards of care.Eli Lilly is also strategically stockpiling Orforglipron, its oral GLP-1 candidate, in anticipation of FDA approval for obesity treatment. This proactive measure aims to prevent supply chain issues seen during previous GLP-1 launches. It reflects an industry-wide focus on ensuring product availability at launch to meet growing market demand effectively.On the regulatory front, there are significant shifts as well. The Trump administration's renewed pilot of 340B rebates aims to optimize drug pricing frameworks. Novartis has secured a long-term supply agreement with Niowave for Actinium-225 (Ac-225), crucial for developing targeted cancer therapies. This highlights the sustained demand for radiopharmaceutical isotopes as part of precision medicine initiatives.Biopharma funding is expected to recover steadily by 2026, albeit with a cautious approach favoring de-risked assets over broader platform technologies. Venture capitalists prefer predictable returns amidst an evolving market landscape.Now, let's turn to Japan, where Innovacell is planning a $92 million IPO on the Tokyo Stock Exchange. This move signals a renewed interest in biotech within the region after a long drought in IPOs. Financial strategies like these are vital for advancing cell therapies that hold promise for treating conditions once deemed challenging.Gilead Sciences has acquired synthetic lethal therapy from Genhouse Bio through a $1.5 billion deal, further underscoring the growing interest in synthetic lethality as a novel cancer treatment approach. This strategy focuses on targeting tumors while sparing normal cells, offering more effective therapies with fewer side effects.In mental health innovations, Compass Pathways has reported positive results from its pivotal trial using psilocybin for treatment-resistant depression. The success of this phase 3 trial highlights the potential role of psychedelics in psychiatric care and could revolutionize mental health treatments by providing new options Support the show

What if cancer could be turned from a killer into a manageable chronic illness with no hair loss, no nausea, and no immunosuppression? In this gripping episode of Startup to Stock Exchange, host Seth Farbman goes deep with James Nathanielsz, CEO of NASDAQ-listed Propanc Biopharma (PPCB). From a 17-year grind raising over $30M, battling economic crashes, COVID, and regulatory wars, to compassionate-use stories where terminal patients defied odds and lived years longer, James reveals the science behind their novel proenzyme therapy PRP. Now NASDAQ-uplisted and gearing up for a landmark Phase 1b first-in-human trial in 2026 targeting advanced solid tumors like pancreatic and ovarian cancers, this could redefine treatment in massive markets. A raw, no-BS conversation on biotech perseverance, integrity in public markets, patient hope, and a potential game-changer that started with one doctor's desperate fight to save lives. Don't miss the underdog story that might just change everything.Seth's CompaniesVstock Transfer – https://www.vstocktransfer.com/Share Media – https://www.sharemedia.co/Listen to the ShowApple Podcasts – https://podcasts.apple.com/us/podcast/seth-farbman-on-podcast-from-startup-to-stock-exchange/id1356667808Spotify – https://open.spotify.com/show/54i7xkWaAALAFrUvk4WZcNConnect with SethLinkedIn – https://www.linkedin.com/in/sethfarbman/Instagram – https://www.instagram.com/sethfarbmanstockTikTok – https://www.tiktok.com/@sethfarbmanTwitter (X) – https://x.com/sethfarbman1About the ShowFrom Startup to Stock Exchange, hosted by entrepreneur and investor Seth Farbman, spotlights the journey of founders and CEOs as they scale their companies from early ideas to public markets. Each episode features candid conversations with leaders across industries, offering insights on growth, fundraising, branding, and the mindset it takes to build a company that lasts.00:48 – Seth introduces James Nathanielsz & Propanc Biopharma (PPCB)02:13 – Rambo scars analogy: 17+ years of entrepreneurial wars03:08 – Propanc today: 17 years, $30M raised, NASDAQ uplist 202503:55 – Seth on the insane conviction needed for 17-year biotech grind08:12 – Core motivation: helping families, belief the drug truly works10:37 – Origin: 28-year-old mom gained 2 extra years via treatment12:34 – 46 compassionate patients: 19 terminal cases beat huge odds, no side effects15:26 – Vision: Turn metastatic cancer into a chronic illness game-changing17:23 – “25 years of overnight success” 32:50 – Get treatment to patients fast, transformative potentialConnect with Seth LinkedIn – https://www.linkedin.com/in/sethfarbman/ Instagram – https://www.instagram.com/sethfarbmanstock TikTok – https://www.tiktok.com/@sethfarbman Twitter (X) – https://x.com/sethfarbman1

Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company's leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.

In this week’s episode of “The Top Line,” Fierce checks in with professional services juggernaut KPMG on the biopharma rebound many industry watchers predicted in the closing months of 2025. Fierce Pharma’s Fraiser Kansteiner sits down with Kristin Cirello Pothier, principal and U.S. and Americas region life sciences sector leader, as well as global deal advisory and strategy leader for health and life sciences at KPMG, to discuss the firm’s latest industry outlook. Pothier also explains how drugmakers are cutting through the noise and reflects on the technology, indication and valuation factors shaping today’s dealmaking appetite. To learn more about the topics in this episode: 2026 forecast: After a surge of M&A in Q4, will the trend continue? Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report In quick reversal, Trump calls off tariff threat related to Greenland pursuit See omnystudio.com/listener for privacy information.

The McCullough Report with Dr. Peter McCullough – America faces a reckoning as critics expose the biopharmaceutical complex behind pandemic policy, vaccine safety failures, and suppressed treatments. Gene Bailey and Dr. Peter McCullough challenge government and corporate narratives, warn of lingering spike protein risks, and call for reclaiming bodily autonomy, medical truth, and cultural sanity amid a broader war on humanity...

The McCullough Report with Dr. Peter McCullough – America faces a reckoning as critics expose the biopharmaceutical complex behind pandemic policy, vaccine safety failures, and suppressed treatments. Gene Bailey and Dr. Peter McCullough challenge government and corporate narratives, warn of lingering spike protein risks, and call for reclaiming bodily autonomy, medical truth, and cultural sanity amid a broader war on humanity...

If you're a physician with at least 5 years of experience looking for a flexible, non-clinical, part-time medical-legal consulting role… ...Dr. Armin Feldman's Medical Legal Coaching program will guarantee to add $100K in additional income within 12 months without doing any expert witness work. Any doctor in any specialty can do this work. And if you don't reach that number, he'll work with you for free until you do, guaranteed. How can he make such a bold claim? It's simple, he gets results…  Dr. David exceeded his clinical income without sacrificing time in his full-time position. Dr. Anke retired from her practice while generating the same monthly consulting income.  And Dr. Elliott added meaningful consulting work without lowering his clinical income or job satisfaction. So, if you're a physician with 5+ years of experience and you want to find out exactly how to add $100K in additional consulting income in just 12 months, go to arminfeldman.com.                                                          =============== Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== Pediatric endocrinologist Dr. Nerissa Kreher shares how she moved from clinical research and fellowship training into the biopharma industry, ultimately serving as chief medical officer at multiple companies and founding Pharma Industry MD Coach. With more than 17 years in biotech and pharma, she now combines executive experience with coaching to help physicians understand what industry careers really look like and how to position themselves for those roles. In this presentation, she compares clinical practice with biopharma work, describes what day-to-day life is like on cross-functional teams, and breaks down the main entry points for physicians—clinical development, pharmacovigilance/drug safety, and medical affairs. She also explains which skills transfer well from clinical medicine, how to think about personality fit, and why learning to balance confidence with humility is crucial when interviewing for industry roles. You'll find links mentioned in the episode at nonclinicalphysicians.com/biopharma-industry/

Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this interview, GT Biopharma (NASDAQ: GTBP) CEO Michael Breen explains why the company is expanding its platform into solid tumors and how its NK engager technology is designed to activate the body's natural immune response.Breen discusses the science behind GTB-5550, why B7H3 is a compelling target across many solid tumors, and how preclinical results support the company's next steps. He also outlines key milestones from 2025 and what investors should watch as GT Biopharma moves toward clinical trials and data readouts in 2026.Learn more about GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=I7-Vd8PO8L0And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia

Our U.S. Biotech and Biopharma analysts Sean Laaman and Terence Flynn discuss the latest developments that could be positioning the healthcare sector for strong outperformance.Read more insights from Morgan Stanley.----- Transcript -----Sean Laaman: Welcome to Thoughts on the Market. I'm Sean Laaman, Morgan Stanley's U.S. Small and Mid-Cap Biotech Analyst. Terence Flynn: And I'm Terence Flynn, Morgan Stanley's U.S. Biopharma Analyst. Sean Laaman: Today, we'll discuss how a rally in the healthcare sector is being driven by more favorable macro conditions. It's Tuesday, October 28th at 10am in New York. So, Terence, healthcare has lagged the broader market year-to-date, and valuations have been near historical lows. But recent weeks show strengthening performance. Policy headwinds have been front and center.What's changed in the regulatory environment and how is the biopharma sector adapting to these pricing and tariff dynamics? Terence Flynn: Sean, as you know, with many other sectors, tariffs were initially a focus earlier this year. But a number of companies in our space have subsequently announced significant U.S. manufacturing investments to reshore supply chains. And hence, the market's less focused on tariffs in our space right now. But the other policy dynamic and focus is what's called Most Favored Nation or MFN drug pricing. Now, this is where the President's been focused on aligning U.S. drug prices with those in other developed countries. And recently we've seen several companies announce agreements with the administration along these lines, which importantly has provided investors with more visibility here. And we're watching to see if additional agreements get announced. Sean Laaman: Got it. Another hurdle for Large-cap biopharma is a looming expiration of patents with [$]177 billion exposed by 2030. How is this shaping M&A trends and strategic priorities? Terence Flynn: For sure. I mean, as you know, Sean, patent expiry is our normal part of the life cycle of drug development. Every company goes through this at some point, but this does put the focus on company's internal pipelines to continue to progress while also being able to access external innovation via M&A. Recently we have started to see a pickup in deal activity, which could bode well for performance in SMID-cap biotech. Sean Laaman: At the same time, you believe relative valuations look compelling for Large-cap biopharma. Where are valuations versus where they've been historically? What's driving this and how should investors think about positioning? Terence Flynn: Absolutely. Look, on a price to earnings multiple, the sector's trading at about a 30 percent discount to the S&P 500 right now. Now that's in line with prior periods of policy uncertainty. But as policy visibility improves, we expect the focus will shift back to fundamentals. Now, positioning to me still feels light here, given some of the patent cliff dynamics we just discussed. Now, Sean, with the Fed moving toward rate cuts, how do you see this impacting your sector on the biotech side? Sean Laaman: Well, Terence, particularly in my space, which is Small- and Mid-cap biotech companies, they're typically capital consumers are not capital producers. They're particularly sensitive to the current rate environment.Therefore, they're sensitive to spending on pipeline. They're sensitive to M&A. So, as rates come down, we expect more spending on pipeline and more M&A activity, which is generally positive for the sector. Looking forward, biotech sector is generally the best performing sector on a six-to-12-month timeframe post the first rate cut. Terence Flynn: Great. You've also talked about this SMID to Big thesis on the biotech side. Can you explain what's driving that? Sean Laaman: Sure Terence. There's three pieces to the SMID to Big thematic. So, we in SMID-cap biotech, we cover 80 to 90 companies. About a third of those are newly, kind of profitable companies. Those companies are turning from being capital consumers to capital producers. We see about $15 billion of cash on balance sheets for 2025, going to north of 130 billion by 2030. That's the first piece. The second piece is due to regulatory uncertainty at the USFDA. We're seeing more attractive valuations amongst clinical stage names. That's the second piece. And third piece relates to your coverage, Terence. I refer back to that [$]177 billion of LOE. So, we expect generally that M&A activity will be quite high amongst our sector. Terence Flynn: And let's not forget about AI, which has implications across the healthcare space. How much is this changing the dynamic in biotech, Sean? Sean Laaman: It is changing, but we're really at the beginning. I think there's three things to think about. The first one is faster trial recruitment. The second one is faster regulatory submissions. And the third one, which is the most interesting, but we're really at the beginning of, is faster time to appropriately targeted molecules. Terence Flynn: Great. And maybe lastly, what are the key risks and catalysts for SMID-cap biotech in the current environment? Sean Laaman: As always, we're focused on pipeline failures in terms of risk. Secondly, in terms of risk, we're looking at regulatory risk at the FDA. And thirdly, we're looking at the rise in China biotech and the competitive dynamic there.Whether you're watching large cap biopharma, M&A moves, or the rise of cash-rich, SMID-cap biotechs, the healthcare sector setup is unlike anything we've seen in years.Terence, thanks for speaking with me. Terence Flynn: Always a pleasure to be on the show. Thanks for having me, Sean. Sean Laaman: And thanks for listening. If you enjoy Thoughts on the Market, please leave us a review wherever you listen and share the podcast with a friend or colleague today.